Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.
Novartis
Novartis
Eli Lilly and Company
Pfizer
Kelonia Therapeutics, Inc.
Quetzal Therapeutics
Orca Biosystems, Inc.
Taiho Oncology, Inc.
Celgene
Cellectar Biosciences, Inc.
Takeda
Cogent Biosciences, Inc.
Eli Lilly and Company
Kedrion S.p.A.
Ossium Health, Inc.
Eli Lilly and Company
Eli Lilly and Company
Pfizer
Constellation Pharmaceuticals
Takeda
Cogent Biosciences, Inc.
Eli Lilly and Company
Novartis
Eli Lilly and Company
Cellenkos, Inc.
Celgene
Seagen Inc.
Celularity Incorporated
Vincerx Pharma, Inc.
Taiho Oncology, Inc.
Astex Pharmaceuticals, Inc.
OriCell Therapeutics Co., Ltd.
Seagen Inc.
Kyowa Kirin Co., Ltd.
Kyowa Kirin Co., Ltd.
AO GENERIUM
Anaveon AG
Limbix Health, Inc.
Sierra Oncology LLC - a GSK company
Pulmotect, Inc.
Celularity Incorporated
Amgen
Takeda
NS Pharma, Inc.
Novartis
Hoffmann-La Roche
Seagen Inc.
Takeda
CTI BioPharma
Gilead Sciences
Novartis